Future research should address key challenges in clinical translation, such as developing selective inhibitors that target pro-tumorigenic TNF-α signaling while maintaining anti-tumor effects, identifying predictive biomarkers to determine which patients may benefit from anti-TNF-α therapies, and optimizing combination strategies with immunotherapy or chemotherapy to prevent resistance mechanisms. This evidence concerns the gene TNF and neoplasm.